

Literaturverzeichnis

Hamburger Ärzteblatt 06 | 2024

Seite 1

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

S. 12 – 17: Endometriose – interdisziplinär behandeln.

Von Julian-Martin Dittmann, Hannah Sältz, Dr. Sami Shihada, Prof. Dr. Rüdiger Klapdor

1. Kennedy S et al. ESHRE guideline for the diagnosis and treatment of endometriosis. Hum. Reprod. Oxf. Engl. 2005;20:2698–2704.
2. Lamceva J, Uljanovs R, Strumfa I. The Main Theories on the Pathogenesis of Endometriosis. Int. J. Mol. Sci. 2023;24:4254.
3. Sampson JA. Metastatic or Embolic Endometriosis, due to the Menstrual Dissemination of Endometrial Tissue into the Venous Circulation. Am. J. Pathol. 1927;3(43):93-110.
4. Sachedina A, Todd N. Dysmenorrhea, Endometriosis and Chronic Pelvic Pain in Adolescents. J. Clin. Res. Pediatr. Endocrinol. 2020;12:7-17.
5. Verkauf BS. Incidence, symptoms, and signs of endometriosis in fertile and infertile women. J. Fla. Med. Assoc. 1987;74:671-675.
6. Davenport S, Smith D, Green DJ. Barriers to a Timely Diagnosis of Endometriosis: A Qualitative Systematic Review. Obstet. Gynecol. 2023;142:571–583.
7. Becker CM et al. ESHRE guideline: Endometriosis. Hum. Reprod. Open 2022, 2022;hoac009.
8. Moura APC et al. Accuracy of transvaginal sonography versus magnetic resonance imaging in the diagnosis of rectosigmoid endometriosis: Systematic review and meta-analysis. PloS One 2019;14:e0214842.
9. Wykes CB, Clark TJ, Kha KS. Accuracy of laparoscopy in the diagnosis of endometriosis: a systematic quantitative review. BJOG Int. J. Obstet. Gynaecol. 2004;111:1204–1212.
10. Kalaitzopoulos DR et al. Treatment of endometriosis: a review with comparison of 8 guidelines. BMC Womens Health 2021;21:397.
11. Burghaus S et al. Diagnosis and Treatment of Endometriosis. Guideline of the DGGG, SGGG and OEGGG (S2k Level, AWMF Registry Number 015/045, August 2020). Geburtshilfe Frauenheilkd. 2021;81:422–446.
12. Barnard ND et al. Nutrition in the prevention and treatment of endometriosis: A review. Front. Nutr. 2023;10:1089891.

Angaben zu möglichen Interessenkonflikten: vorhanden

Prof. Dr. Rüdiger Klapdor: Wissenschaftlicher Beirat für Planttec Medical, Übernahme von Reisekosten von Intuitive Surgical

S. 25: Bilder aus der klinischen Medizin: Chronische xanthogranulomatöse Cholezystitis.

Von Dr. Christa Schmidt, Prof. Dr. Guntram Lock

1. Uptodate: Shyam Varadarajulu MD et al. Xanthogranulomatous cholecystitis, Jul 13, 2023.
2. Tannapfel A, Klöppel G, Remmele W. Pathologie Leber, Gallenwege und Pankreas. Springer Verlag: 3. Aufl., 2020.
3. Giudicelli X, Rode A, Bancel et al. Xanthogranulomatous cholecystitis: Diagnosis and management. J Visc Surg .2021 Aug;158(4):326-336. doi: 10.1016/j.jvisurg.2021.02.004. Epub 2021 Mar 23.
4. Rahman J et al. Xanthogranulomatous Cholecystitis: A Diagnostic Challenge for Radiologists, Surgeons and Pathologists. Cureus 12(8):2020.
5. Singh VR et al. Xanthogranulomatous cholecystitis what every radiologist should know. Woeld J Radiol.(2016);28:183-191.
6. Suzuki H et al. Xanthogranulomatous cholecystitis: Difficulty in differentiating from gallbladder cancer. World Journal of Gastroenterology 21(35):2015, 10166-10173.

Literaturverzeichnis

Hamburger Ärzteblatt 06 | 2024

Seite 2

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

- Zhuang PY et al. Xanthogranulomatous cholecystitis: a clinicopathological study of its association with gallbladder carcinoma. *J Dig Dis.* 2013;14:45-50.
- Godman ZD, Ishak KG. Xanthogranulomatous cholecystitis. *Am J Surg Pathol.* 1981;5:653-659.

S. 26 – 28: Perspektiven der Therapie zur Cholesterinsenkung.

Von Prof. Dr. Franz Rinninger, Prof. Dr. Eberhard Windler, Prof. Dr. Jörg Heeren, Prof. Dr. Frank-Ulrich Beil

- Domanski MJ, Tian X, Wu CO, Reis et al. Time course of LDL cholesterol exposure and cardiovascular disease event risk. *J Am Coll Cardiol.* 2020;76:1507-16.
- Vissers FLJ, Mach F, Smulders YM et al. ESC guidelines on cardiovascular disease prevention in clinical practice. *Eur Heart J* 2021;42:3227-337.
- Murphy SA, Cannon CP, Blazing MA et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome. *J Am Coll Cardiol* 2016;67:353-61.
- Laufs U, Böhm M, Kroemer HK, Schüssel K, Griesse N, Schulz M. Strategien zur Verbesserung der Einnahmetraue von Medikamenten. *Dtsch Med Wochenschr* 2011;136: 1616-21.
- Ray KK, Bays HE, Catapano AL et al. Safety and efficiency of bempedoic acid to reduce LDL cholesterol. *N Engl J Med* 2019;380:1022-32.
- Nissen SE, Lincoff AM, Brennan D et al. Bempedoic acid and cardiovascular outcomes in statin-intolerant patients. *N Engl J Med* 2023;388:1353-64.
- Dullaart RPF. PCSK9 inhibition to reduce cardiovascular events. *N Engl J Med* 2017;376:1790-91.
- Thiery J, Burkhardt R. PCSK9 – “missing link” der familiären Hypercholesterinämie. *Herz* 2016;41:281-9.
- Sabatine MS, Giugliano RP, Keech AC et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. *N Engl J Med* 2017;376:1713-22.
- Ference BA, Ginsberg HN, Graham I et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease. 1. Evidence from genetic, epidemiologic, and clinical studies. A consensus statement from the European Atherosclerosis Society Consensus panel. *Eur Heart J* 2017;38:2459-72.
- Cohen JC, Boerwinkle E, Mosley TH, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. *N Engl J Med* 2006;354:1264.
- Khvorova A. Oligonucleotide therapeutics – a new class of cholesterol-lowering drugs. *N Engl J Med* 2017;376: 4-7.
- Frank-Kamenetsky M, Grefhorst A, Anderson NN et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in non-human primates. *Proc Natl Acad Sci. USA* 2008;105:11915-20.
- Fitzgerald K, Frank-Kamenetsky M, Morskaya SS et al. Effect of an RNA interference drug on the synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9) and the concentration of serum LDL cholesterol in healthy volunteers: a randomized, single-blind, placebo-controlled, phase 1 trial. *Lancet* 2014; 383: 60-68.
- Fitzgerald K, White S, Borodovsky A et al. A highly durable RNAi therapeutic inhibitor of PCSK9. *N Engl J Med* 2017;376: 41-51.
- Ray KK, Wright R, Kallend E et al. Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol. *N Engl J Med* 2020;382:1507-19.

Literaturverzeichnis

Hamburger Ärzteblatt 06 | 2024

Seite 3

Weidestr. 122 b

22083 Hamburg

Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

- Fachinformation Inclisiran (Leqvio®), Novartis, März 2022
- Oostveen RF, Khera AV, Kathiresan S et al. New approaches for targeting PCSK9: small-interfering ribonucleic acid and genome editing. *Arterioscler Thromb Vasc Biol* 2023;43:1081-92.
- Musunuru KJ. Moving toward genome-editing therapies for cardiovascular diseases. *J Clin Invest* 2022;132:1-8.
- Musunuru K, Chadwick AC, Mizoguchi T et al. In vivo CRISPR base editing of PCSK9 durably lowers cholesterol in primates. *Nature* 2021;593:429-38.
- Lee RG, Mazzola AM, Braun MC et al. Efficacy and safety of an investigational single course CRISPR base-editing therapy targeting PCSK9 in non-human primates and mouse models. *Circulation* 2023;147:242-53.
- Kaiser J. Rewriting DNA in the body lowers cholesterol. *Science* 2023;382:751.
- Hoekstra M, Van Eck M, Van Berkel TJC. Perspective: Hepatocyte-directed base editing as novel treatment for human dyslipidemia – current status and remaining challenges. *Arterioscler Thromb Vasc Biol* 2023;43:832-35.

Angaben zu möglichen Interessenkonflikten: vorhanden

Beil: 1 Online Vortrag 2022 für DACH e.V. /Synlab

Prof. Dr. J. Heeren: Honorare im Rahmen von Fortbildungsveranstaltungen erhalten von: Ferring Arzneimittel, Novartis Pharma GmbH, Sanofi-Aventis Deutschland GmbH, Lilly Deutschland GmbH, AMGEN GmbH, MSD Sharp Dohme GmbH, Daichi Sankyo Deutschland GmbH

Eberhard Windler: Vortragstätigkeit für Firma Daiichi Sankyo und Beratung der Firma Daiichi Sankyo.

S. 30 – 31: Der besondere Fall: Parkinsonismus durch Hirntumor verursacht.

Von Valeria Sajin, Sina Heiling, Dr. Seza Bolat, PD Dr. Jürgen Eggers, Dr. Torsten Rosenkranz

- Tolosa E, Garrido A, Scholz SW, Poewe W. Challenges in the diagnosis of Parkinson's disease. *Lancet Neurol*. 2021 May;20(5):385-397. doi: 10.1016/S1474-4422(21)00030-2. PMID: 33894193; PMCID: PMC8185633.
- Bloem BR, Okun MS, Klein C. Parkinson's disease. *Lancet*. 2021 Jun 12;397(10291):2284-2303. doi: 10.1016/S0140-6736(21)00218-X. Epub 2021 Apr 10. PMID: 33848468.
- Singer, Harvey S., Mink, Jonathan W, Gilbert, Donald L, Jankovic, Joseph. *Movement Disorders in Childhood (Third Edition)*. Parkinsonism. 2022, 395–413. <https://doi.org/10.1016/B978-0-12-820552-5.00022-X>.
- Jankovic J. Parkinson's disease: clinical features and diagnosis. *J Neurol Neurosurg Psychiatry*. 2008 Apr;79(4):368-76. doi: 10.1136/jnnp.2007.131045. PMID: 18344392.
- Bienkowski M, Furtner J, Hainfellner JA. Clinical neuropathology of brain tumors. *Handb Clin Neurol*. 2017;145:477-534. doi: 10.1016/B978-0-12-802395-2.00032-8. PMID: 28987190.
- Byun YH, Park CK. Classification and Diagnosis of Adult Glioma: A Scoping Review. *Brain Neurorehabil*. 2022 Nov 22;15(3):e23. doi: 10.12786/bn.2022.15.e23. PMID: 36742083; PMCID: PMC9833487.
- Berger TR, Wen PY, Lang-Orsini M, Chukwueke UN. World Health Organization 2021 Classification of Central Nervous System Tumors and Implications for Therapy for Adult-Type Gliomas: A Review. *JAMA Oncol*. 2022 Oct 1;8(10):1493-1501. doi: 10.1001/jamaoncol.2022.2844. PMID: 36006639.
- Cahill D, Turcan S. Origin of Gliomas. *Semin Neurol*. 2018 Feb;38(1):5-10. doi: 10.1055/s-0037-1620238. Epub 2018 Mar 16. PMID: 29548046.

Literaturverzeichnis

Hamburger Ärzteblatt 06 | 2024

Seite 4

Weidestr. 122 b
22083 Hamburg
Redaktion

E-Mail: verlag@aekhh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

9. Koshy M, Villano JL, Dolecek TA, Howard A, Mahmood U, Chmura SJ, et al. Improved survival time trends of glioblastoma using the SEER 17 population-based registries. *J Neuro Oncol.* 2012;107(1):207–12.
10. Cedergren Weber G, Timpka J, Rydelius A, Bengzon J, Odin P. Tumoral parkinsonism-Parkinsonism secondary to brain tumors, paraneoplastic syndromes, intracranial malformations, or oncological intervention, and the effect of dopaminergic treatment. *Brain Behav.* 2023 Aug;13(8):e3151. doi: 10.1002/brb3.3151. Epub 2023 Jul 11. PMID: 37433071; PMCID: PMC10454247.
11. Leong YQ, Lee SWH, Ng KY. Cancer risk in Parkinson disease: An updated systematic review and meta-analysis. *Eur J Neurol.* 2021 Dec;28(12):4219-4237. doi: 10.1111/ene.15069. Epub 2021 Sep 12. PMID: 34403556.
12. Tang CF, Lu MK, Muo CH, Tsai CH, Kao CH. Increased risk of brain tumor in patients with Parkinson's disease: a nationwide cohort study in Taiwan. *Acta Neurol Scand.* 2016 Aug;134(2):148-53. doi: 10.1111/ane.12524. Epub 2015 Oct 28. PMID: 26508469.
13. Mencke P, Hanss Z, Boussaad I, Sugier PE, Elbaz A, Krüger R. Bidirectional Relation Between Parkinson's Disease and Glioblastoma Multiforme. *Front Neurol.* 2020 Aug 20;11:898. doi: 10.3389/fneur.2020.00898. PMID: 32973662; PMCID: PMC7468383.
14. Reddy KK, Anderson MD, Vijayakumar S, Vengaloor Thomas T. Parkinson's Syndrome After Cranial Radiotherapy: A Case Report. *Cureus.* 2022 Apr 23;14(4):e24411. doi: 10.7759/cureus.24411. PMID: 35619842; PMCID: PMC9126036.
15. Mehanna R, Jimenez-Shahed J, Itin I. Three Cases of Levodopa-Resistant Parkinsonism After Radiation Therapy. *Am J Case Rep.* 2016 Dec 2;17:916-920. doi: 10.12659/ajcr.900537. PMID: 27909286; PMCID: PMC5138068.
16. Chuang C, Constantino A, Balmaceda C, Eidelberg D, Frucht SJ. Chemotherapy-induced parkinsonism responsive to levodopa: an underrecognized entity. *Mov Disord.* 2003 Mar;18(3):328-331. doi: 10.1002/mds.10344. PMID: 12621638.
17. Garg A, Sinha S. Doxorubicin induced aggregation of α -synuclein: Insights into the mechanism of drug induced Parkinsonism. *Colloids Surf B Biointerfaces.* 2022 Apr;212:112371. doi: 10.1016/j.colsurfb.2022.112371. Epub 2022 Jan 29. PMID: 35131711.
18. Xing F, Marsili L, Truong DD. Parkinsonism in viral, paraneoplastic, and autoimmune diseases. *J Neurol Sci.* 2022 Feb 15;433:120014. doi: 10.1016/j.jns.2021.120014. Epub 2021 Oct 1. PMID: 34629181.
19. Yamamoto T, Fukaya C, Obuchi T, Watanabe M, Ohta T, Kobayashi K, Oshima H, Yoshino A. Glioblastoma Multiforme Developed during Chronic Deep Brain Stimulation for Parkinson Disease. *Stereotact Funct Neurosurg.* 2016;94(5):320-325. doi: 10.1159/000448925. Epub 2016 Oct 11. PMID: 27723655.
20. Höllerhage M. Secondary parkinsonism due to drugs, vascular lesions, tumors, trauma, and other insults. *Int Rev Neurobiol.* 2019;149:377-418. doi: 10.1016/bs.irn.2019.10.010. Epub 2019 Nov 21. PMID: 31779822.
21. Krauss JK, Paduch T, Mundinger F, Seeger W. Parkinsonism and rest tremor secondary to supratentorial tumours sparing the basal ganglia. *Acta Neurochir (Wien).* 1995;133(1-2):22-9. doi: 10.1007/BF01404943. PMID: 8561031.
22. Bhatoe HS. Movement disorders caused by brain tumours. *Neurol India.* 1999 Mar;47(1):40-2. PMID: 10339706.
23. Kim JI, Choi JK, Lee JW, Hong JY. Intracranial Meningioma-induced Parkinsonism. *J Lifestyle Med.* 2014 Sep;4(2):101-3. doi: 10.15280/jlm.2014.4.2.101. Epub 2014 Sep 30. PMID: 26064861; PMCID: PMC4391021.
24. Choi MS, Choi B, Cho SJ, Kim JY, Kwon KH, Kang SY. Cortical tumor presenting with Parkinsonism. *Iran J Neurol.* 2015 Oct 7;14(4):219-21. PMID: 26885341; PMCID: PMC4754601.
25. Saleh C, Akhalbedashvili N, Hund-Georgiadis M. Brain Tumor Presenting with Parkinsonism. *Case Rep Neurol.* 2021 Sep 13;13(3):595-597. doi: 10.1159/000518198. PMID: 34703448; PMCID: PMC8460956.

Literaturverzeichnis

Hamburger Ärzteblatt 06 | 2024

Seite 5

Weidestr. 122 b
22083 Hamburg
Redaktion

E-Mail: verlag@aekeh.de

Tel.: (040) 20 22 99 – 205

Fax: (040) 20 22 99 – 400

26. Chang DC, Lin JJ, Lin JC. Parkinsonism as an initial manifestation of brain tumor. *Zhonghua Yi Xue Za Zhi (Taipei)*. 2000 Aug;63(8):658-62. PMID: 10969454.
27. Hirata K, Yokota T, Miura Y. Teaching Neurolmages: Parkinsonism Secondary to a Metastatic Lesion Involving the Substantia Nigra. *Neurology*. 2021 Mar 30;96(13):e1800-e1801. doi: 10.1212/WNL.0000000000011162. Epub 2020 Nov 9. PMID: 33168703.
28. Ho BL, Lieu AS, Hsu CY. Hemiparkinsonism secondary to an infiltrative astrocytoma. *Neurologist*. 2008 Jul;14(4):258-61. doi: 10.1097/NRL.0b013e31816c43ea. PMID: 18617854.
29. Semra Ari, Parkinsonism secondary to metastatic brain tumor: A case report *J Neurol Disord* 2018, Volume 6 DOI: 10.4172/2329-6895-C5-038
30. Benincasa D, Romano A, Mastronardi L, Pellicano C, Bozzao A, Pontieri FE. Hemiparkinsonism due to frontal meningioma. *Acta Neurol Belg*. 2008 Mar;108(1):29-32. PMID: 18575186.
31. Salvati M, Frati A, Ferrari P, Verrelli C, Artizzu S, Letizia C. Parkinsonian syndrome in a patient with a pterional meningioma: case report and review of the literature. *Clin Neurol Neurosurg*. 2000 Dec;102(4):243-245. doi: 10.1016/s0303-8467(00)00111-6. PMID: 11154814.
32. Tolosa E, Wenning G, Poewe W. The diagnosis of Parkinson's disease. *Lancet Neurol*. 2006 Jan;5(1):75-86. doi: 10.1016/S1474-4422(05)70285-4. PMID: 16361025.

Angaben zu möglichen Interessenkonflikten: keine